
The launch of the new hearing device Jabra Enhance Plus, which is developed by GN Hearing, now depends on the US Food and Drug Administration (FDA), as the company has sent the product off for evaluation, CEO Gitte Aabo tells MedWatch in an interview.
Earlier this month, GN had to acknowledge that certain product milestones hadn't been reached, and thus a 2021 launch was no longer on the table. Consequently, the hearing aid manufacturer downgraded its financial guidance for the year, and let its former Head of Research and Development Pär Thureson go.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app